<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04830930</url>
  </required_header>
  <id_info>
    <org_study_id>A73_04FDI2102</org_study_id>
    <nct_id>NCT04830930</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Effect of Food on the PK, PD of CKD-381 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, Crossover Study to Investigate the Effect of Food on the Pharmacokinetics and Pharmacodynamics of CKD-381 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to investigate the effect of food on the Pharmacokinetics and pharmacodynamics of&#xD;
      CKD-381 in healthy volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, single-dose, crossover study to investigate the effect of food on&#xD;
      the pharmacokinetics and pharmacodynamics of CKD-381 in healthy volunteers&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 21, 2021</start_date>
  <completion_date type="Actual">July 26, 2021</completion_date>
  <primary_completion_date type="Actual">June 17, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Crossover Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0-24 hours</time_frame>
    <description>maximum observed concentration after dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Area under the plasma concentration versus time curve over the dosing interval after dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent decrease from baseline in integrated gastric acidity for 24-hour interval after dose</measure>
    <time_frame>0-24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>GERD</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: fasted condition/ Period 2: fed condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: fed condition/ Period 2: fasted condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-381</intervention_name>
    <description>single-dose, oral administration of CKD-381 1 tablet</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Between 19 aged and 50 aged in healthy adult&#xD;
&#xD;
          2. Body weight more than 55.0kg and body mass index over 18.0kg/m2 and under 30.0kg/m2&#xD;
&#xD;
          3. Have negative result on Helicobacter Pylori antibody test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have clinically significant disease that hepatobiliary system, kidney, nervous system,&#xD;
             immune system, respiratory system, endocrine system, hemato-oncology disease,&#xD;
             cardiovascular system or mental illness, or a history of mental disease.&#xD;
&#xD;
          2. Have a gastrointestinal disease history(including surgery) that can effect evaluation&#xD;
             of safety, pharmacokinetics and pharmacodynamics of investigational product.&#xD;
&#xD;
          3. Hypersensitivity reaction or clinically significant hypersensitivity reaction in the&#xD;
             history of investigational product, additives or benzimidazole family.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyungsang Yu, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>ksyu@snu.ac.kr</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-gu</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CKD-381</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

